CN114931635A - 治疗阿尔茨海默病的方法 - Google Patents

治疗阿尔茨海默病的方法 Download PDF

Info

Publication number
CN114931635A
CN114931635A CN202210397435.9A CN202210397435A CN114931635A CN 114931635 A CN114931635 A CN 114931635A CN 202210397435 A CN202210397435 A CN 202210397435A CN 114931635 A CN114931635 A CN 114931635A
Authority
CN
China
Prior art keywords
subject
aria
antibody
patient
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210397435.9A
Other languages
English (en)
Chinese (zh)
Inventor
B.P.布特
J.J.塞维尼
L.L.威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen International Neuroscience GmbH
Original Assignee
Biogen International Neuroscience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen International Neuroscience GmbH filed Critical Biogen International Neuroscience GmbH
Publication of CN114931635A publication Critical patent/CN114931635A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202210397435.9A 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法 Pending CN114931635A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US62/346,818 2016-06-07
US201662435531P 2016-12-16 2016-12-16
US62/435,531 2016-12-16
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease
CN201780044190.9A CN109476730A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780044190.9A Division CN109476730A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Publications (1)

Publication Number Publication Date
CN114931635A true CN114931635A (zh) 2022-08-23

Family

ID=59067640

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210397435.9A Pending CN114931635A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN202210397569.0A Pending CN114796481A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN201780044190.9A Pending CN109476730A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210397569.0A Pending CN114796481A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN201780044190.9A Pending CN109476730A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Country Status (12)

Country Link
US (3) US20200308259A1 (cg-RX-API-DMAC7.html)
EP (1) EP3464350A1 (cg-RX-API-DMAC7.html)
JP (3) JP2019517540A (cg-RX-API-DMAC7.html)
KR (2) KR20230165883A (cg-RX-API-DMAC7.html)
CN (3) CN114931635A (cg-RX-API-DMAC7.html)
AU (2) AU2017276656A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018075300A2 (cg-RX-API-DMAC7.html)
CA (1) CA3026598A1 (cg-RX-API-DMAC7.html)
IL (1) IL263433B2 (cg-RX-API-DMAC7.html)
MA (1) MA45149A (cg-RX-API-DMAC7.html)
MX (1) MX2018015022A (cg-RX-API-DMAC7.html)
WO (1) WO2017211827A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
SG11202110504XA (en) 2019-03-26 2021-10-28 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
CN114599393A (zh) * 2019-10-22 2022-06-07 比奥根Ma公司 治疗阿尔茨海默病的抗β-淀粉样蛋白抗体
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
EP4351643A4 (en) * 2021-06-07 2025-08-06 Biogen Ma Inc METHODS OF TREATMENT OF ALZHEIMER'S DISEASE
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
CA3237165A1 (en) * 2021-11-19 2023-05-25 Jeng-Horng Her Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy
CN122175980B (zh) * 2026-05-12 2026-07-17 四川大学华西医院 一种淀粉样蛋白相关影像学异常的磁共振图像随访方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ607881A (en) * 2006-07-14 2014-11-28 Genentech Inc Humanized antibody against amyloid beta
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
KR102308915B1 (ko) * 2012-10-15 2021-10-06 메디뮨 리미티드 아밀로이드 베타에 대한 항체
EP2928494A4 (en) * 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
NZ723884A (en) * 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
KR20230165883A (ko) 2023-12-05
CA3026598A1 (en) 2017-12-14
AU2017276656A1 (en) 2018-12-13
US20260193332A1 (en) 2026-07-09
EP3464350A1 (en) 2019-04-10
JP2019517540A (ja) 2019-06-24
KR20190021311A (ko) 2019-03-05
IL263433B2 (en) 2024-03-01
US20220281963A1 (en) 2022-09-08
IL263433B1 (en) 2023-11-01
CN114796481A (zh) 2022-07-29
US20200308259A1 (en) 2020-10-01
MA45149A (fr) 2019-04-10
JP2022145965A (ja) 2022-10-04
AU2024216442A1 (en) 2024-10-17
BR112018075300A2 (pt) 2019-04-30
WO2017211827A1 (en) 2017-12-14
MX2018015022A (es) 2019-08-14
JP2025160337A (ja) 2025-10-22
IL263433A (en) 2019-01-31
CN109476730A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
US20260091109A1 (en) Method for Treating Alzheimer's Disease
US20220281963A1 (en) Methods for treating alzheimer's disease
CN114599393A (zh) 治疗阿尔茨海默病的抗β-淀粉样蛋白抗体
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
JP2024540294A (ja) アルツハイマー病を治療するための方法
TW202313111A (zh) 治療阿茲海默症之方法
NZ788486A (en) Methods for treating Alzheimer's disease
CN118829445A (zh) 用于治疗阿尔茨海默病的方法
EA051351B1 (ru) Способ лечения болезни альцгеймера

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination